Shares of China Biologic Products Inc. (NASDAQ:CBPO) were up 3.6% during trading on Wednesday . The stock traded as high as $112.35 and last traded at $112.05, with a volume of 109,237 shares. The stock had previously closed at $108.15.

Several analysts have commented on CBPO shares. Zacks Investment Research lowered shares of China Biologic Products from a “hold” rating to a “sell” rating in a report on Tuesday, March 29th. Jefferies Group restated a “buy” rating on shares of China Biologic Products in a report on Saturday, June 4th. Finally, Credit Suisse Group AG upgraded shares of China Biologic Products from a “neutral” rating to an “outperform” rating in a report on Tuesday. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $139.20.

The firm has a market capitalization of $2.99 billion and a PE ratio of 33.60. The stock’s 50-day moving average is $111.51 and its 200-day moving average is $117.90.

China Biologic Products (NASDAQ:CBPO) last posted its earnings results on Wednesday, May 4th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.06. The business earned $85.60 million during the quarter, compared to the consensus estimate of $74 million. The business’s revenue was up 21.6% on a year-over-year basis. Equities research analysts predict that China Biologic Products Inc. will post $4.29 EPS for the current fiscal year.

In related news, Director Wp X. Biologics Llc sold 2,775,000 shares of the company’s stock in a transaction dated Wednesday, June 8th. The shares were sold at an average price of $111.00, for a total transaction of $308,025,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Ming Yin sold 19,618 shares of the company’s stock in a transaction dated Friday, May 20th. The shares were sold at an average price of $113.64, for a total transaction of $2,229,389.52. Following the transaction, the vice president now owns 51,419 shares in the company, valued at $5,843,255.16. The disclosure for this sale can be found here.

Other institutional investors have recently modified their holdings of the company. ProShare Advisors LLC purchased a new position in shares of China Biologic Products during the fourth quarter valued at approximately $3,040,000. WCM Investment Management CA increased its position in shares of China Biologic Products by 22.8% in the fourth quarter. WCM Investment Management CA now owns 60,753 shares of the biopharmaceutical company’s stock valued at $8,655,000 after buying an additional 11,282 shares during the last quarter. CI Investments Inc. increased its position in shares of China Biologic Products by 22.7% in the fourth quarter. CI Investments Inc. now owns 55,600 shares of the biopharmaceutical company’s stock valued at $7,921,000 after buying an additional 10,300 shares during the last quarter. Russell Frank Co increased its position in shares of China Biologic Products by 69.1% in the fourth quarter. Russell Frank Co now owns 14,104 shares of the biopharmaceutical company’s stock valued at $1,993,000 after buying an additional 5,764 shares during the last quarter. Finally, Calamos Advisors LLC increased its position in shares of China Biologic Products by 0.6% in the fourth quarter. Calamos Advisors LLC now owns 43,630 shares of the biopharmaceutical company’s stock valued at $6,216,000 after buying an additional 270 shares during the last quarter.

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.